Russ Altman

[6] His primary research interests are in the application of computing and informatics technologies to problems relevant to medicine.

He is particularly interested in methods for understanding drug action at molecular, cellular, organism and population levels.

His lab studies how human genetic variation impacts drug response, helping start the PharmGKB project in 2000.

[7] Other work focuses on the analysis of biological molecules to understand the actions, interactions and adverse events of drugs, publishing a database called FEATURE in 2003.

[10] He chaired the Science Board advising the FDA Commissioner, serves on the NIH director’s advisory committee, and is co-chair of the IOM Drug Forum.

In 2011 along with three other faculty members including Euan Ashley, Atul Butte, Michael Snyder and businessman John West.